"Every three minutes, a person in the US is diagnosed with blood cancer. Genomic testing can have a significant impact on research and understanding of these cancers, but we need to bring more testing to internal labs where results can be readily available to healthcare professionals, "he said. Garret hampton, President of Next Generation Clinical Sequencing at Thermo Fisher Scientific. "Oncomine's new immune repertoire assays unlock the power of NGS to help researchers quickly obtain an enormous amount of information about a lymphoid cancer sample, including its prevalence and understanding of how it is evolving."
One of the challenges of current NGS-based immunological repertoire analysis has been the need to run multiple secondary tests due to the high test failure rates of a typical single NGS assay. The new Oncomine panclonality assays overcome this challenge by uniquely targeting multiple receptor sites to reduce the need for secondary testing and increase the likelihood that a single assay can detect a potentially malignant clone.
"With the ability to sequence multiple targets in a single reaction, our team is now able to get much more information from an assay compared to single-target NGS tests," said Dr. John DeCoteau, medical director, University of Saskatchewan, Advanced Diagnostic Research Laboratory. "With Oncomine's BCR panclonality assay, we were able to achieve a 93 percent positive clonality detection rate in a multiple myeloma sample cohort, without the need for secondary testing. That provides a marked improvement for laboratory efficiency and it allows us to get results faster. "
Thermo Fisher's The new suite of immune repertoire assays is available on the Ion GeneStudio S5 system and features built-in data visualization and analysis tools that simplify the interpretation of results for laboratories and healthcare professionals.
For more information on these trials, visit oncomine.com/clonality.
* For research use only. It should not be used in diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in the service of science, with annual revenues exceeding $ 30 billion. Our mission is to enable our customers to make the world healthier, cleaner and safer. Whether our clients are accelerating life science research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their labs, we are here to help. Our global team of more than 80,000 colleagues offers an unmatched combination of innovative technologies, shopping convenience, and pharmaceutical services through our industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. For more information please visit www.thermofisher.com.
Media contact information:
Mauricio Minotta
Phone: 760-805-5266
Email: [emailย protected]
Jessika parry
Phone: 419-266-4016
Email: [emailย protected]
SOURCE Thermo Fisher Scientific
